Inclusion criteria (phase I):
* Patient indicated for cardiac pacing according to the most recent guidelines from the European Society of Cardiology (ESC)
* Patient planned for a de novo implantation of any Single Chamber (SR) or Dual Chamber (DR) CE marked pacemaker
* Patient planned for a catheter-guided implantation in the interventricular septum area
* Patient planned for the implantation of any CE marked ventricular pacing lead compatible with the FLEXIGO delivery catheter
* Patient reviewed, signed and dated the Informed Consent Form (ICF)
Inclusion criteria (phase II):
* Patient indicated for cardiac pacing or CRT according to the most recent guidelines from the ESC
* Patient planned for a de novo implantation of any SR or DR CE marked pacemaker, or any CE marked CRT-D
* Patient planned for a catheter-guided implantation in the interventricular septum area
* Patient planned for the implantation of any CE marked ventricular pacing lead compatible with the FLEXIGO delivery catheter
* Patient reviewed, signed and dated the ICF
Exclusion criteria (phase I):
* Patient planned for a device upgrade, or a device or a lead replacement
* Patient with a congenital heart disease
* Patient with significant hypertrophic cardiomyopathy, cardiac amyloidosis or obstructive hypertrophic cardiomyopathy
* Patient with a Left Ventricular Ejection Fraction (LVEF) ≤ 35%
* Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device)
* Patient implanted despite a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient contraindicated for a single dose of 310 μg of dexamethasone sodium phosphate, patient implanted with a tricuspid replacement heart valve, with prior tricuspid valve intervention or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery)
* Minor age patient (i.e. under 18 years of age)
* Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation
* Non-menopausal women
Exclusion criteria (phase II):
* Patient planned for a device upgrade, or a device or a lead replacement
* Patient with a congenital heart disease
* Patient with significant hypertrophic cardiomyopathy, cardiac amyloidosis or obstructive hypertrophic cardiomyopathy
* Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device)
* Patient implanted despite a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient contraindicated for a single dose of 310 μg of dexamethasone sodium phosphate, patient implanted with a tricuspid replacement heart valve, with prior tricuspid valve intervention or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery)
* Minor age patient (i.e. under 18 years of age)
* Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation
* Non-menopausal women
